new hope for patients with this “cancer killer” virus

As human beings continue to evolve constantly, many believe that this is the science which will allow us to reach a new decisive stage in this evolution. We had already revealed to you how it was now possible to stop aging thanks to these scientists who rejuvenate your cellsbut a recent announcement could also be synonymous with hope, especially in the fight against cancer.

the experimental virus cf33-hnis

Indeed, a new experimental virus called “cancer killer” has been administered to a human patient for the first timein the hope that these trials may reveal a new way to effectively fight cancerous tumors in the human body.

This virus, known as CF33-hNIS or Vaxiniais what is called a oncolytic virus, which have been thought to exclusively infect cancer cells by taking advantage of characteristics unique to these abnormal cells, thus sparing healthy cells. This type of virus has thus been considered as being able to be the future of cancer therapies.

And in the case of Vaxinia, the genetically modified virus enters the cells and duplicates itself. After a while, the infected cell bursts, releasing thousands of new virus particles which then act as antigens, thereby stimulating the immune system to attack nearby cancer cells.

Previous research done on animals showed that the virus could mobilize the immune system in this way in order to hunt and destroy cancer cells, but no testing had been done in humans until now.

the first human trial

But that has just changed, since City of Hopea cancer care and research center based in Los Angeles, as well as the Australian company Imugene specialized in biotechnology, having participated in the development of Vaxinia, recently announced that the first clinical trial on human patients was in progress. Daneng Li, oncologist at City of Hope and Principal Investigator, explained:

Our previous research has shown that oncolytic viruses can stimulate the immune system to respond to and kill cancer, but also to respond better to other immunotherapies, including checkpoint inhibitor treatments. .

Now is the time to boost the power of immunotherapy, and we believe CF33-hNIS has the potential to improve outcomes for our patients in their fight against cancer.

But in order to be sure of this potential, Vaxinia must first pass its first trials on human patients and show that it is safe, the first phase of the trial being focused on the safety and tolerability of this solution. The process should recruit a hundred participants in total in Australia and the United States, each of whom is an adult patient with advanced tumors who has already tried at least two standard treatments. Treatment should last approximately 24 months.

The version of the virus that is currently undergoing clinical trials produces human sodium iodide symporter (hNIS), a protein that allows researchers to visualize and monitor viral replication, and provides an additional way to damage cancer cells by adding radioactive iodine.

However, before determining the effectiveness of this solution, researchers will first examine how patients react, recording the frequency and severity of any adverse effects, and examining how participants react when the low doses are increased. Secondary measures, in particular the evaluation of the effectiveness of CF33-hNIS in reducing treated tumors, will be analyzed later. But given that the trial is expected to last at least two years, it will probably be some time before we can know the results in detail.

a virus that brings hope

Once the safety of Vaxinia has been demonstratedsome participants will also receive an immunotherapy drug called pembrolizumab, which improves the immune system’s ability to fight cancer-causing cells. Doctor Yuman Fongthe Sangiacomo Family Chair in Surgical Oncology at City of Hope and the main designer of the genetically engineered virus, said:

Interestingly, the same characteristics that make cancer cells resistant to chemotherapy or radiation therapy actually enhance the success of oncolytic viruses, such as CF33-hNIS.

We hope to harness the promise of virology and immunotherapy for the treatment of a wide variety of deadly cancers.

Leslie Chong, CEO of Imugenethen said:

Dosing the first patient in our Vaxinia study is an important milestone for Imugene and clinicians facing the challenge of treating advanced metastatic solid tumors. Professor Yuman Fong and the City of Hope team have conducted outstanding research. In addition to the positive preclinical results, we are incredibly eager to exploit the potential of Vaxinia and oncolytic virotherapy.

If the drug is found to be safe and well tolerated, then we could be in the presence of a powerful new solution in the fight against cancerdescribed as “game changing due to its potency and ability to recruit and activate immune cells”according to Surgical Oncologist Susanne Warner, who previously led a team studying the effects of CF33 on tumors in mice. She said:

Our oncolytic virus trains the immune system to target a specific cancer cell. Which means that if a similar cancer cell ever tries to regrow, the immune system will be ready.

And while oncolytic viruses have appeared as real avenues to explore for several years, their success had so far been very limited. And if no one yet knows for sure if Vaxinia will work the same wonders in humans, if it proves to be effective, it would only be the second viral oncolytic therapy approved by the Food and Drug Administration (FDA), after a drug called Talimogene laherparepvec (known as T-Vec or Imlygic), a modified version of the herpes simplex virus, which is used in the treatment of melanoma.

And to know more about these new neurons discovered in the human brain which have never been observed elsewhere, see our previous article on the subject, right here.

Leave a Comment